Table 3.
Geometric means and 95% CI of cardiometabolic and endocrine biomarkers by quartiles of total activity counts per day, Women’s Lifestyle Validation Studies, United States, 2010–2012.
| Quartiles of Total Activity Counts per Day | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 (median=387,250) | 2 (median=511,739) | 3 (median=624,002) | 4 (median=792,067) | P-trend | |||||
| Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | ||
| Pro-Insulin (pmol/L), n=470 | |||||||||
| Model 1a | 19.7 | 18.0, 21.6 | 19.2 | 17.6, 20.9 | 17.8 | 16.0, 19.8 | 15.7 | 14.1, 17.5 | 0.0023 |
| Model 2b | 18.4 | 16.8, 20.1 | 18.8 | 17.3, 20.4 | 18.5 | 16.7, 20.4 | 17.1 | 15.4, 19.1 | 0.33 |
| C-peptide (ng/ml), n=525 | |||||||||
| Model 1a | 6.86 | 6.68, 7.04 | 6.69 | 6.53, 6.86 | 6.27 | 6.09, 6.45 | 6.40 | 6.22, 6.59 | 0.0003 |
| Model 2b | 6.72 | 6.54, 6.89 | 6.66 | 6.50, 6.81 | 6.33 | 6.16, 6.51 | 6.55 | 6.37, 6.74 | 0.13 |
| Insulin (mU/ml), n=453 | |||||||||
| Model 1a | 8.09 | 7.18, 9.12 | 7.07 | 6.33, 7.90 | 6.72 | 5.82, 7.75 | 5.58 | 4.79, 6.50 | 0.0004 |
| Model 2b | 7.27 | 6.51, 8.12 | 7.03 | 6.36, 7.77 | 7.15 | 6.28, 8.14 | 6.26 | 5.44, 7.19 | 0.14 |
| IGFBP-3 (ng/ml), n=524 | |||||||||
| Model 1a | 3.71 | 3.57, 3.86 | 3.63 | 3.50, 3.77 | 3.71 | 3.55, 3.88 | 3.87 | 3.70, 4.05 | 0.13 |
| Model 2b | 3.73 | 3.58, 3.88 | 3.63 | 3.50, 3.77 | 3.70 | 3.54, 3.87 | 3.86 | 3.69, 4.04 | 0.21 |
| IGF-1 (ng/ml), n=524 | |||||||||
| Model 1a | 104 | 98, 110 | 100 | 95, 106 | 103 | 97, 110 | 114 | 107, 121 | 0.0235 |
| Model 2b | 105 | 99, 112 | 100 | 95, 106 | 103 | 96, 109 | 112 | 105, 120 | 0.11 |
| Adiponectin (μg/ml), n=526 | |||||||||
| Model 1a | 10.2 | 9.2, 11.2 | 12.2 | 11.1, 13.4 | 14.3 | 12.8, 16.0 | 15.8 | 14.2, 17.7 | <.0001 |
| Model 2b | 11.0 | 9.9, 12.1 | 12.5 | 11.4, 13.6 | 13.8 | 12.4, 15.3 | 14.5 | 13.0, 16.2 | 0.0004 |
| Leptin (ng/ml), n=524 | |||||||||
| Model 1a | 39.6 | 35.6, 44.0 | 32.4 | 29.3, 35.7 | 27.5 | 24.4, 30.9 | 21.4 | 19.0, 24.1 | <.0001 |
| Model 2b | 33.6 | 30.9, 36.5 | 31.1 | 28.9, 33.5 | 29.9 | 27.4, 32.7 | 25.5 | 23.3, 28 | <.0001 |
| Leptin-sR (ng/ml), n=524 | |||||||||
| Model 1a | 27.6 | 26.3, 28.9 | 28.7 | 27.5, 30.0 | 32.3 | 30.6, 34.0 | 34.4 | 32.7, 36.3 | <.0001 |
| Model 2b | 29.0 | 27.7, 30.3 | 29.0 | 27.9, 30.2 | 31.5 | 30.1, 33.0 | 32.7 | 31.1, 34.3 | 0.0002 |
Abbreviations: IGFBP-3, insulin-like growth factor binding protein 3; IGF-1, insulin-like growth factor 1; Leptin-sR, leptin soluble receptor.
Model 1: Adjusted for age (continuous), Caucasian (yes/no), age at menopause (continuous), age at menarche (<12, 12, 13, 14+ years), parity and age at first birth (nulliparous, 1–2 children at <25 y at first birth, 1–2 children at 25+ y at first birth, 3+ children at < 25 y at first birth, 3+ children at 25+ y at first birth), postmenopausal status and post-menopausal hormone use (premenopausal, never, past, current use), smoking status (never, past, current 1–14 cigs/day, current 15+ cigs/day), alcohol intake (0, 0,1 – <5, 5 – <15, 15+ g/day), multivitamin use (yes.no), family history of cancer (yes/no), caffeine intake (quartiles), total fiber intake (quartiles) and total accelerometer wear time (hours/day, continuous).
Model 2: Model 1 + adjusted for body mass index (kg/m2, continuous).